Compare Hims and Hers Health Inc (HIMS) vs TORM plc (TRMD) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

TRMD trades at $38.92, down 0.33% on the day, with strong technical momentum showing a bullish moving average signal despite RSI_6 indicating potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 35.52% net income margin and attractive valuation metrics including a 6.59 P/E ratio. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates.

The outlook remains positive with 100% analyst buy ratings and improving cash flow projections for 2026. Key risks include spot rate volatility in the tanker market and recent insider selling activity. The stock offers value characteristics with strong dividend potential but faces near-term headwinds from declining contracted rates.